GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Clinical Kidney Journal · 22.11.2024 · 17 (Supplement_2) · ii19-ii35
DOI: 10.1093/ckj/sfae296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 22.11.2024. Verfasst von Daria Abasheva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sociedad Española de Nefrología, Sociedad Madrileña de Nefrología, Fundación Renal Iñigo Álvarez de Toledo.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular–kidney–metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) ≥30 kg/m2] or with overweight (BMI ≥27 kg/m2) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others. Additionally, liraglutide and semaglutide are approved to reduce CVD risk in patients with CVD and T2DM. Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial). Thus, nephrologists should consider prescribing GLP-1 RAs to improve metabolic control, reduce CVD risk or improve kidney outcomes in three scenarios: patients with overweight and a related comorbid condition such as hypertension, dyslipidaemia or CVD, patients with obesity and patients with T2DM. This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
- RICORS2040 Madrid, Spain.
- Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
ORCID-Profile: Alberto Ortiz, Beatriz Fernandez-Fernandez
Förderung
- Sociedad Española de Nefrología
- Sociedad Madrileña de Nefrología
- Fundación Renal Iñigo Álvarez de Toledo
- Comunidad de Madrid en Biomedicina
- Instituto de Salud Carlos III
- Fondo de investigación Sanitaria/Fondo Europeo de Desarrollo regional
- ERA-PerMed-
- European Union—NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia
Zitieren
APA
Abasheva, D., Ortiz, A., & Fernandez-Fernandez, B. (2024). GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clinical Kidney Journal, 17(Supplement_2), ii19-ii35. https://doi.org/10.1093/ckj/sfae296
Vancouver
Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clinical Kidney Journal. 2024;17(Supplement_2):ii19-ii35. doi:10.1093/ckj/sfae296
BibTeX
@article{Abasheva2024,
author = {Abasheva, Daria and Ortiz, Alberto and Fernandez-Fernandez, Beatriz},
title = {GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {Supplement_2},
pages = {ii19--ii35},
doi = {10.1093/ckj/sfae296}
}
EUVIMED